C O M M U N I C A T I O N S
come from nuclease resistance of ds-SDNA.3 With more research,
ds-SDNA could be developed as a new DNA device for gene-
silencing.
In conclusion, we prepared 4′-thio-dTTP and 4′-thio-dCTP and
investigated their susceptibility for PCR amplification. Ds-SDNAs
were amplified sufficiently by KOD dash DNA polymerase under
appropriate conditions. The resulting 4′-thioDNAs acted as tem-
plates for transcription not only in vitro but also in mammalian
cells to afford RNA which showed gene-silencing effects via RNAi
machinery. Unlike nucleoside triphosphates modified on their
nucleobase and phosphorus positions,8,9 no example of PCR
amplification using sugar-modified nucleoside triphosphates is
known. While pioneering investigations of PCR amplification using
RS-dNTPs and in vitro transcription has been carried out using the
resulting modified DNA,10 to the best of our knowledge, the
potential of ds-SDNA for transcription in cells as reported in this
study is the first reported application with modified nucleic acids.
Thus, these results suggested the importance of SDNA when
implementing an enzymatic approach to produce not only aptamers
by SELEX but also new DNA devices for gene-silencing via RNAi
machinery.
Figure 3. Ultraviolet image from ethidium bromide-stained 2.5% agarose
gel of the transcriptional products by T7 RNA polymerase (Full image of
the gel was presented in the Supporting Information). The reaction mixture
contains DNA104 as a template and NTPs (lane 1); SDNA104+1 as a
template and NTPs (lane 2); SDNA104+2 as a template and NTPs (lane
3); and SDNA104+1,2 as a template and NTPs (lane 4). The transcriptional
products were quantified by RiboGreen as 0.47 µg/mL (lane 1, 100%), 0.23
µg/mL (lane 2, 49%), 0.21 µg/mL (lane 3, 45%), and 0.18 µg/mL (lane 4,
38%).
Figure 4. Gene silencing of the expression of pGL3 luciferase gene using
scramble ds-DNA (lane 1), natural ds-DNA (lane 2), SDNA+1 (lane 3),
SDNA+2 (lane 4), and SDNA+1,2 (lane 5). Data are averages of three
independent experiments.
Acknowledgment. This work was supported in part by Grant-
in-Aid from the Japan Society for Promotion of Science.
Supporting Information Available: Synthesis of 1 and 2, PCR
amplification, in vitro transcription, and transcription in NIH/3T3 cells
resulting gene-silencing. This material is available free of charge via
sequence of ds-DNA (or ds-SDNAs) by PCR, which was expected
to act as templates for transcription in cells by RNA polymerase
III (pol III), with the resulting short-hairpin RNA (shRNA) showing
a gene-silencing effect via RNAi machinery.7
References
Thus, only specific parts of the shRNA expression vector
(pSIREN-Shuttle-Luc) consisting of a U6 promoter and a gene of
interest (pGL3 luciferase) were amplified by PCR in the presence
of 1 and/or 2 (approximately 300 bp in length). The efficiency of
amplification of the ds-SDNAs4 relative to the natural ds-DNA was
as follows: SDNA+1, 51%; SDNA+2, 99%; SDNA+1,2, 11%.
The resulting ds-SDNAs were then used for gene-silencing experi-
ments. Cotransfection of individually amplified ds-SDNA (or ds-
DNA) and reporter plasmids (pGL3 control vector) into NIH/3T3
cells was carried out, and the potency of gene-silencing, RNAi
activity, after 24 h was evaluated on the basis of luminescence
activity by luciferase. The reporter plasmids included secreted
alkaline phosphatase (SEAP) gene as an internal standard, and the
luminescence activity was normalized on the basis of SEAP activity
to correct the transcription efficiency of each experiment (see the
Supporting Information). As shown in Figure 4, the natural ds-
DNA inhibited gene expression by approximately 40% relative to
conditions using a scramble ds-DNA. Since the gene-silencing that
occurred was sequence specific, we postulated that it is due to RNAi
arising from the formation of shRNA in cells from the transfected
ds-DNA. Either SDNA+1 and SDNA+2 or SDNA+1,2 showed
the RNAi activity with similar potency. Since SDNA+1,2 consists
of a 50% ratio of 2′-deoxy-4′-thionucleoside units in the whole
sequence, including the U6 promoter and target sequence parts,
the fact that transcription occurred in the cells in this modified ds-
DNA is worth noting. In addition, SDNA+2 has a higher RNAi
activity than that of unmodified ds-DNA. Although the transcription
efficiency in vitro from SDNA104+2 was lower than the natural
DNA template (Figure 3), the susceptibility toward pol III in cells
may differ from the in vitro results. Alternatively, this trend may
(1) For examples: (a) Srivatsan, S. G.; Tor, Y. J. Am. Chem. Soc. 2007, 129,
2044-2053. (b) Weisbrod, S. H.; Marx, A. Chem. Commun. 2007, 1828-
1830. (c) Ichida, J. K.; Zou, K.; Horhota, A.; Yu, B.; McLaughlin, L. W.;
Szostak, J. W. J. Am. Chem. Soc. 2005, 127, 2802-2803. (d) Seo, T. S.;
Bai, X.; Kim, D. H.; Meng, Q.; Shi, S.; Ruparel, H.; Li, Z.; Turro, N. J.;
Ju, J. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 5926-5931. (e) Carrasco,
N.; Huang, Z. J. Am. Chem. Soc. 2004, 126, 448-449.
(2) For examples about susceptibility of sugar-modified nucleoside triphos-
phates: (a) Peng, C. G.; Damha, M. J. J. Am. Chem. Soc. 2007, 129,
5310-5311. (b) Renders, M.; Emmerechts, G.; Rozenski, J.; Krecmerova´,
M.; Holy´, A.; Herdewijn, P. Angew. Chem., Int. Ed. 2007, 46, 2501-
2504. (c) Veedu, R. N.; Vester, B.; Wengel, J. ChemBioChem 2007, 8,
490-492. (d) Chaput, J. C.; Szostak, J. W. J. Am. Chem. Soc. 2003, 125,
9274-9275. (e) Ono, T.; Scalf, M.; Smith, L. M. Nucleic Acids Res. 1997,
25, 4581-4588.
(3) Inoue, N.; Minakawa, N.; Matsuda, A. Nucleic Acids Res. 2006, 34, 3476-
3483.
(4) In this paper, double-stranded DNA products containing 4′-thio-dT and/
or 4′-thio-dC were refered to ds-SDNAs. Furthermore, ds-SDNAs were
classified into SDNA104+1 (containing 4′-thio-dT), SDNA104+2 (con-
taining 4′-thio-dC), and SDNA104+1,2 (containing 4′-thio-dT and 4′-
thio-dC) in the text and Figures 2 and 3. Ds-SDNAs described in Figure
4 were classified into SDNA+1, SDNA+2, and SDNA+1,2.
(5) (a) Inoue, N.; Kaga, D.; Minakawa, N.; Matsuda, A. J. Org. Chem. 2005,
70, 8597-8600. (b) Secrist, J. A., III; Tiwari, K. N.; Riordan, J. M.;
Montogomery, J. A. J. Med. Chem. 1991, 34, 2361-2366.
(6) Kato, Y.; Minakawa, N.; Komatsu, Y.; Kamiya, H.; Ogawa, N.; Harashima,
H.; Matsuda, A. Nucleic Acids Res. 2005, 33, 2942-2951.
(7) (a) Sui, G.; Soohoo, C.; Affar, E. B.; Gay, F.; Shi, Y.; Forrester, W. C.;
Shi, Y. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 5515-5520. (b) Taki, M.;
Kato, Y.; Miyagishi, M.; Takagi, Y.; Taira, K. Angew. Chem., Int. Ed.
2004, 43, 3160-3163.
(8) (a) Sismour, A. M.; Benner, S. A. Nucleic Acids Res. 2005, 33, 5640-
5646. (b) Kawate, T.; Allerson, C. R.; Wolfe, J. L. Org. Lett. 2005, 7,
3865-3868. (c) Seela, F.; Roling, A. Nucleic Acids Res. 1992, 20, 55-
61.
(9) Porter, K. W.; Briley, J. D.; Shaw, B. R. Nucleic Acids Res. 1997, 25,
1611-1617.
(10) Ciafre`, S. A.; Rinaldi, M.; Gasparini, P.; Seripa, D.; Bisceglia, L.; Zelante,
L.; Farace, M. G.; Fazio, V. M. Nucleic Acids Res. 1995, 23, 4134-4142.
JA075953C
9
J. AM. CHEM. SOC. VOL. 129, NO. 50, 2007 15425